Expert Panel Offers Practical Guidelines for Optimizing Epidiolex Dosing in Rare Epilepsies | Research

The takeaway

A seven-member expert panel used a modified Delphi method to develop consensus recommendations for initiating, titrating, and optimizing Epidiolex (pharmaceutical CBD) for seizures in Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.

Neurologists and epileptologists prescribing Epidiolex; caregivers of patients with LGS, Dravet syndrome, or TSC.

FDA-approved for 3 rare epilepsy syndromes: LGS, Dravet, and TSC

What the researchers found

Key recommendations include individualizing starting dose and titration rate based on baseline variables and prior medication responses, differentiating Epidiolex from non-approved CBD products, managing drug-drug interactions (particularly with clobazam and valproate), and tracking maximum tolerated dose as a measure of effectiveness.

Why it matters

Despite FDA approval, confusion persists among healthcare providers, patients, and caregivers about how to dose Epidiolex optimally and how it differs from over-the-counter CBD products. These real-world practice guidelines fill a gap between clinical trial protocols and everyday clinical decision-making.

The numbers in context

Seven expert panelists with epilepsy expertise. Two rounds of Delphi discussion. Two broad themes: overcoming barriers to initiation and optimization of treatment. Epidiolex is approved for three conditions: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.

How the study worked

Modified Delphi consensus method. Seven epilepsy specialists completed a premeeting survey based on literature review, then discussed findings over two rounds to reach consensus on recommendation statements for Epidiolex treatment in LGS, DS, and TSC.

What this study cannot tell us

Consensus-based recommendations reflect expert opinion, not randomized trial evidence for specific dosing strategies. The panel of seven experts, while experienced, represents a small group. Recommendations may not apply to patients with other types of epilepsy.

How to read the evidence

Moderate: structured expert consensus using Delphi methodology, informed by clinical trial data and real-world prescribing experience, but not based on new clinical trial evidence.

When this study was published

2024 consensus recommendations.

The bigger picture

Epidiolex was the first FDA-approved cannabis-derived medication. As prescribing experience grows, real-world insights from experienced clinicians become valuable for the broader medical community, especially given the confusion between pharmaceutical CBD and unregulated CBD products that persists among both providers and patients.

Questions still open

How do real-world Epidiolex outcomes compare to clinical trial results? Could these dosing optimization strategies be validated through prospective clinical studies?

Common questions

How is Epidiolex different from store-bought CBD?

Epidiolex is a pharmaceutical-grade, FDA-approved CBD product with standardized dosing, verified purity, and established safety monitoring. Over-the-counter CBD products lack this regulation, and studies have shown inconsistent potency and potential contaminants.

Why does Epidiolex dosing need to be individualized?

Patients vary in their baseline medications, prior treatment responses, and ability to tolerate side effects. Drug-drug interactions, particularly with clobazam and valproate, can significantly affect how Epidiolex is metabolized and its side effect profile.

Read the original research

Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.

Epilepsia open, 9(5), 1632-1642

View on PubMed ↗Publisher’s paper ↗

Citation

Wechsler, Robert T; Burdette, David E; Gidal, Barry E; Hyslop, Ann; McGoldrick, Patricia E; Thiele, Elizabeth A; Valeriano, James. (2024). Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.. Epilepsia open, 9(5), 1632-1642. https://doi.org/10.1002/epi4.12956